

Paolo Gandellini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6133524/publications.pdf>

Version: 2024-02-01

55
papers

2,854
citations

172457

29
h-index

189892

50
g-index

55
all docs

55
docs citations

55
times ranked

7052
citing authors

#	ARTICLE	IF	CITATIONS
1	miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma. <i>Cancer Gene Therapy</i> , 2022, 29, 1394-1404.	4.6	3
2	Coding the noncoding: 2 years of advances in the field of microRNAs and long noncoding RNAs. <i>Cancer Gene Therapy</i> , 2021, 28, 355-358.	4.6	1
3	Noncoding RNAs in the Interplay between Tumor Cells and Cancer-Associated Fibroblasts: Signals to Catch and Targets to Hit. <i>Cancers</i> , 2021, 13, 709.	3.7	7
4	Biological relevance and therapeutic potential of G-quadruplex structures in the human noncoding transcriptome. <i>Nucleic Acids Research</i> , 2021, 49, 3617-3633.	14.5	50
5	Prediction of Grade Reclassification of Prostate Cancer Patients on Active Surveillance through the Combination of a Three-miRNA Signature and Selected Clinical Variables. <i>Cancers</i> , 2021, 13, 2433.	3.7	8
6	miR-1227 Targets SEC23A to Regulate the Shedding of Large Extracellular Vesicles. <i>Cancers</i> , 2021, 13, 5850.	3.7	2
7	Unveiling the ups and downs of miR-205 in physiology and cancer: transcriptional and post-transcriptional mechanisms. <i>Cell Death and Disease</i> , 2020, 11, 980.	6.3	36
8	SPOP Deregulation Improves the Radiation Response of Prostate Cancer Models by Impairing DNA Damage Repair. <i>Cancers</i> , 2020, 12, 1462.	3.7	8
9	miR-1272 Exerts Tumor-Suppressive Functions in Prostate Cancer via HIP1 Suppression. <i>Cells</i> , 2020, 9, 435.	4.1	11
10	Gene expression dataset of prostate cells upon MIR205HG/LEADR modulation. <i>Data in Brief</i> , 2020, 29, 105139.	1.0	4
11	Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models. <i>Journal of Controlled Release</i> , 2019, 308, 44-56.	9.9	41
12	LEADeR role of miR-205 host gene as long noncoding RNA in prostate basal cell differentiation. <i>Nature Communications</i> , 2019, 10, 307.	12.8	44
13	Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations. <i>European Urology Oncology</i> , 2019, 2, 277-285.	5.4	7
14	miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKC δ and ZEB1 inhibition. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 51.	8.6	64
15	Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. <i>EBioMedicine</i> , 2019, 39, 215-225.	6.1	41
16	Predicting and Understanding Cancer Response to Treatment. <i>Disease Markers</i> , 2018, 2018, 1-2.	1.3	2
17	miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis. <i>Cancer Letters</i> , 2017, 395, 53-62.	7.2	80
18	microRNAs as players and signals in the metastatic cascade: Implications for the development of novel anti-metastatic therapies. <i>Seminars in Cancer Biology</i> , 2017, 44, 132-140.	9.6	42

#	ARTICLE	IF	CITATIONS
19	Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. <i>Journal of Hematology and Oncology</i> , 2017, 10, 19.	17.0	40
20	miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells. <i>Journal of Hematology and Oncology</i> , 2017, 10, 140.	17.0	23
21	PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells. <i>Toxicology and Applied Pharmacology</i> , 2016, 310, 9-19.	2.8	33
22	Dissecting the role of microRNAs in prostate cancer metastasis: implications for the design of novel therapeutic approaches. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 2531-2542.	5.4	22
23	MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs. <i>Current Drug Targets</i> , 2016, 17, 257-265.	2.1	5
24	MicroRNAs in Cancer Management: Big Challenges for Small Molecules. <i>BioMed Research International</i> , 2015, 2015, 1-2.	1.9	17
25	Targeting MicroRNAs to Withstand Cancer Metastasis. <i>Methods in Molecular Biology</i> , 2015, 1218, 415-437.	0.9	11
26	Complexity in the tumour microenvironment: Cancer associated fibroblast gene expression patterns identify both common and unique features of tumour-stroma crosstalk across cancer types. <i>Seminars in Cancer Biology</i> , 2015, 35, 96-106.	9.6	85
27	Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. <i>Oncotarget</i> , 2015, 6, 13119-13132.	1.8	39
28	Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation. <i>Oncotarget</i> , 2015, 6, 31441-31460.	1.8	55
29	Abstract 19: Antitumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. , 2015, , .		0
30	miR-205 Hinders the Malignant Interplay Between Prostate Cancer Cells and Associated Fibroblasts. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 1045-1059.	5.4	63
31	miRNAs in tumor radiation response: bystanders or participants?. <i>Trends in Molecular Medicine</i> , 2014, 20, 529-539.	6.7	40
32	Senescent stroma promotes prostate cancer progression: The role of miR-210. <i>Molecular Oncology</i> , 2014, 8, 1729-1746.	4.6	102
33	Mesenchymal to amoeboid transition is associated with stem-like features of melanoma cells. <i>Cell Communication and Signaling</i> , 2014, 12, 24.	6.5	77
34	miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. <i>Biochemical Pharmacology</i> , 2014, 87, 579-597.	4.4	83
35	MicroRNA-dependent Regulation of Telomere Maintenance Mechanisms: A Field as Much Unexplored as Potentially Promising. <i>Current Pharmaceutical Design</i> , 2014, 20, 6404-6421.	1.9	14
36	Large oncosomes mediate intercellular transfer of functional microRNA. <i>Cell Cycle</i> , 2013, 12, 3526-3536.	2.6	189

#	ARTICLE	IF	CITATIONS
37	Abstract B18: MiR-205 puts the brakes on the malignant interplay between prostate cancer cells and associated fibroblasts. , 2013, , .		1
38	MicroRNAs: Cobblestones on the Road to Cancer Metastasis. <i>Critical Reviews in Oncogenesis</i> , 2013, 18, 341-355.	0.4	36
39	MicroRNA-Mediated Control of Prostate Cancer Metastasis: Implications for the Identification of Novel Biomarkers and Therapeutic Targets. <i>Current Medicinal Chemistry</i> , 2013, 20, 1566-1584.	2.4	15
40	RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 69-78.	2.1	12
41	Reciprocal Metabolic Reprogramming through Lactate Shuttle Coordinately Influences Tumor-Stroma Interplay. <i>Cancer Research</i> , 2012, 72, 5130-5140.	0.9	438
42	miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. <i>Cell Death and Differentiation</i> , 2012, 19, 1750-1760.	11.2	77
43	MicroRNAs as new therapeutic targets and tools in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 265-279.	3.4	81
44	MicroRNAs in Prostate Cancer: A Possible Role as Novel Biomarkers and Therapeutic Targets?. , 2011, , 145-162.		0
45	miR-21: an oncomir on strike in prostate cancer. <i>Molecular Cancer</i> , 2010, 9, 12.	19.2	189
46	Emerging role of microRNAs in prostate cancer: implications for personalized medicine. <i>Discovery Medicine</i> , 2010, 9, 212-8.	0.5	25
47	Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation. <i>British Journal of Cancer</i> , 2009, 100, 739-746.	6.4	47
48	miR-205 Exerts Tumor-Suppressive Functions in Human Prostate through Down-regulation of Protein Kinase C β . <i>Cancer Research</i> , 2009, 69, 2287-2295.	0.9	334
49	Targeting the telosome: Therapeutic implications. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2009, 1792, 309-316.	3.8	37
50	Towards the definition of prostate cancer-related microRNAs: where are we now?. <i>Trends in Molecular Medicine</i> , 2009, 15, 381-390.	6.7	54
51	Photochemically enhanced delivery of a cell-penetrating peptide nucleic acid conjugate targeting human telomerase reverse transcriptase: effects on telomere status and proliferative potential of human prostate cancer cells. <i>Cell Proliferation</i> , 2007, 40, 905-920.	5.3	24
52	Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. <i>Biochemical Pharmacology</i> , 2007, 73, 1703-1714.	4.4	45
53	Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. <i>European Journal of Cancer</i> , 2005, 41, 624-634.	2.8	80
54	Clusterin: A potential target for improving response to antiestrogens. <i>International Journal of Oncology</i> , 1992, 33, 791.	3.3	4

#	ARTICLE	IF	CITATIONS
55	MIR205HG/LEADR Long Noncoding RNA Binds to Primed Proximal Regulatory Regions in Prostate Basal Cells Through a Triplex- and Alu-Mediated Mechanism. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	6